BenzingaOctober 23, 2026 at 1:41 AM NY4 Days Ago
BTIG Maintains Buy on Avalo Therapeutics, Lowers Price Target to $10
BTIG analyst Julian Harrison maintains Avalo Therapeutics (NASDAQ:AVTX) with a Buy and lowers the price target from $58 to $10.
What This Story Means
Claude is explaining the story in plain words…
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site: Benzinga
